Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 studyDiana Cortés‐Selva, Raluca Verona, Clarissa Uhlar et al.|Blood|2024Cited by 60
Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1Diana Cortés‐Selva, Raluca Verona, Tineke Casneuf et al.|Blood|2022Cited by 46
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Suzette Girgis, Liviawati S. Wu et al.|Targeted Oncology|2023Cited by 46
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamabMarie‐Emilie Willemin, Suzette Girgis, Shun Xin Wang Lin et al.|CPT Pharmacometrics & Systems Pharmacology|2024Cited by 6
Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple MyelomaXin Miao, Honghui Zhou, Liviawati S. Wu et al.|Blood|2022Cited by 5